ストックスクリーナーアプリを入手
0.2746
0.59%
0.0016
アフターアワーズ：
.29
0.0154
+5.61%
前日終値:
$0.273
開ける：
$0.273
24時間の取引高:
126.46K
Relative Volume:
0.06
時価総額：
$3.12M
収益：
$1.75M
当期純損益:
$-5.68M
株価収益率:
-0.0564
EPS:
-4.8726
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-4.65%
1か月 パフォーマンス:
-15.77%
6か月 パフォーマンス:
+9.53%
1年 パフォーマンス:
-77.49%
1日の値動き範囲:
$0.2516
$0.2746
1週間の範囲:
$0.2516
$0.29
52週間の値動き範囲:
$0.197
$1.79
Scisparc Ltd Stock (SPRC) Company Profile
SPRC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SPRC
Scisparc Ltd
|
0.2746 | 3.12M | 1.75M | -5.68M | 0 | -4.8726 |
|
VRTX
Vertex Pharmaceuticals Inc
|
490.47 | 128.67B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
585.49 | 60.99B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
599.87 | 36.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
236.75 | 29.89B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
252.77 | 25.74B | 3.81B | -644.79M | -669.77M | -6.24 |
Scisparc Ltd (SPRC) 最新ニュース
Thinking Of Selling SciSparc Ltd (NASDAQ: SPRC) Stock? Check This Out First - Stocksregister
SciSparc Extends Deadline for Miza III Ventures Deal - TipRanks
SciSparc Ltd. Extends Merger Agreement with AutoMax Motors - TipRanks
SciSparc Ltd. (NASDAQ:SPRC) Short Interest Up 1,435.0% in March - Defense World
SciSparc announces resale of 61.21M shares by selling shareholders; shares down - MSN
SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement - Louisiana First News
SciSparc and Clearmind Advance Cocaine Addiction Treatment with South Korean Patent Application - TipRanks
Is the SciSparc Ltd (NASDAQ:SPRC) stock an investment opportunity? - US Post News
SciSparc-Clearmind Collaboration Leads to Publication of - GlobeNewswire
SciSparc Shares Are Soaring Monday: What's Going On? - Benzinga
Scisparc, Clearmind apply for patent in South Korea for its co-developed treatment to overcome cocaine addiction - Marketscreener.com
SciSparc announces publication of patent via Clearmind collaboration - TipRanks
SciSparc-Clearmind Collaboration Leads to Publication of Patent Application for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Ltd. and Clearmind Medicine Inc. Announce Patent Application for Combination Treatment of Cocaine Addiction - Nasdaq
Clearmind Medicine Announces Publication of Patent for Cocaine Addiction Psychedelic Combination Treatment in South Korea - The Manila Times
SciSparc Extends $2 Million Loan to Support Automax?s Growth Following Automax?s Entry into Direct Import of JAC Electric Vehicles - Marketscreener.com
SciSparc Ltd. Agrees to Sell MitoCareX to N2OFF - TipRanks
SciSparc signs definitive agreement to sell MitoCareX to N2OFF - TipRanks
SciSparc to sell MitoCareX to N2Off for $700,000 - MSN
SciSparc divests MitoCareX stake for $700,000 and stock swa By Investing.com - Investing.com South Africa
SciSparc divests MitoCareX stake for $700,000 and stock swa - Investing.com
SciSparc Ltd. Announces Sale of MitoCareX Shares to N2Off for $700,000 and Stock Exchange Agreement - Nasdaq
SciSparc Signs Definitive Agreement to Sell MitoCareX, - GlobeNewswire
SciSparc's Strategic Exit: How Its MitoCareX Sale Could Deliver $2.3M+ in Value - StockTitan
SciSparc Ltd. announced that it expects to receive $2 million in funding from Yorkville Advisors Global LP - Marketscreener.com
SciSparc Extends $2 Million Loan to Support AutoMax's - GlobeNewswire
SciSparc provides $2 million loan to AutoMax for expansion - Investing.com Australia
SciSparc Enters $4.2M Securities Agreement and Supports AutoMax Expansion with $2M Loan - TipRanks
SciSparc provides $2 million loan to AutoMax for expansion By Investing.com - Investing.com South Africa
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles - The Manila Times
SciSparc extends $2M loan to support AutoMax growth - TipRanks
SciSparc Ltd. Enters $2 Million Loan Agreement with AutoMax Motors to Support Business Expansion - Nasdaq
SciSparc Bets $2M on Electric Vehicle Future with Latest AutoMax Financing - StockTitan
N2OFF to acquire biotech firm MitoCareX in strategic move - Investing.com
SciSparc Ltd. Reaches Favorable Lawsuit Settlement, Secures Cash Compensation and IP Rights - TipRanks
How Are Things Looking For SciSparc Ltd (NASDAQ: SPRC) For The Short Term? - Stocks Register
SciSparc Reveals Favorable Cash Settlement In Lawsuit, Shares Up - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology - The Manila Times
SciSparc Ltd. Secures Settlement Agreement in Lawsuit Against Former Directors, Retaining Key Intellectual Property Rights - Nasdaq
SciSparc Secures Favorable Settlement in Lawsuit It Filed, - GlobeNewswire
Legal Victory: SciSparc Claims $411K Settlement and Complete IP Control in Strategic Court Win - StockTitan
Investor Ideas New Stocks to Watch in Life Sciences and AI - Investorideas.com newswire
SPRC’s Market Quandary: Decoding the Ups and Downs of 2023 - The InvestChronicle
SciSparc Ltd (SPRC) Shares Soar Above 1-Year High - The News Heater
Views of Wall Street’s Leading Experts on SciSparc Ltd - SETE News
Behind SciSparc Ltd’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - GlobeNewswire
SciSparc and Clearmind’s Patent Publication Marks Progress in Binge Behavior Treatment - TipRanks
SciSparc Ltd.-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico - Marketscreener.com
SciSparc Ltd. and Clearmind Medicine Inc. Collaborate on Patent Application for Innovative Combination Therapy to Address Binge Behaviors - Nasdaq
Clearmind Medicine Announces Publication of Patent for Binge Behavior Psychedelic Combination Treatment in Mexico - The Manila Times
Scisparc Ltd (SPRC) 財務データ
収益
当期純利益
現金流量
EPS
1.00%
大文字化:
|
ボリューム (24 時間):